These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 363003)

  • 21. US Congress to consider limits on DTCA.
    Guthrie P
    CMAJ; 2007 May; 176(10):1404. PubMed ID: 17485685
    [No Abstract]   [Full Text] [Related]  

  • 22. Expanded access to investigational drugs for treatment use. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2009 Aug; 74(155):40900-45. PubMed ID: 19691173
    [TBL] [Abstract][Full Text] [Related]  

  • 23. American Society of Clinical Oncology policy statement: oversight of clinical research.
    American Society of Clinical Oncology
    J Clin Oncol; 2003 Jun; 21(12):2377-86. PubMed ID: 12721281
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Investigational exemption procedures for new drugs.
    Simmons HE
    JAMA; 1970 Sep; 213(11):1902-4. PubMed ID: 4917639
    [No Abstract]   [Full Text] [Related]  

  • 25. New FDA drug approval policies and HIV vaccine development.
    Mariner WK
    Am J Public Health; 1990 Mar; 80(3):336-41. PubMed ID: 2305921
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Accelerated approval of oncology products: the food and drug administration experience.
    Johnson JR; Ning YM; Farrell A; Justice R; Keegan P; Pazdur R
    J Natl Cancer Inst; 2011 Apr; 103(8):636-44. PubMed ID: 21422403
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug development history, "overview," and what are GCPs?
    Heilman RD
    Qual Assur; 1995 Mar; 4(1):75-9. PubMed ID: 8520867
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recent developments help the defense of drug companies in 10b-5 cases.
    Salpeter AN; Hutchins H
    Food Drug Law J; 1996; 51(3):345-53. PubMed ID: 11797711
    [No Abstract]   [Full Text] [Related]  

  • 29. Tort claims and federal regulation of medical devices vs pharmaceuticals.
    Green M
    JAMA; 2009 Sep; 302(11):1169; author reply 1169-70. PubMed ID: 19755694
    [No Abstract]   [Full Text] [Related]  

  • 30. Pharmaceuticals and medical devices: FDA oversight. End-of-year issue brief.
    Chaps NA
    Issue Brief Health Policy Track Serv; 2010 Jan; ():1-31. PubMed ID: 20217914
    [No Abstract]   [Full Text] [Related]  

  • 31. [Diagnostic kits in parasitology: which controls?].
    Rossi P
    Parassitologia; 2004 Jun; 46(1-2):145-9. PubMed ID: 15305705
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safe drugs and the cost of good intentions.
    Eichler HG; Abadie E; Raine JM; Salmonson T
    N Engl J Med; 2009 Apr; 360(14):1378-80. PubMed ID: 19339718
    [No Abstract]   [Full Text] [Related]  

  • 33. Regulations and procedures for new drug evaluation and approval in China.
    Yin H
    Hum Gene Ther; 2006 Oct; 17(10):970-4. PubMed ID: 16958562
    [No Abstract]   [Full Text] [Related]  

  • 34. Development and approval of vaccines in the United States.
    Botstein P
    Isr J Med Sci; 1986; 22(3-4):268-71. PubMed ID: 3528047
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Challenges in drug development for muscle disease: a stakeholders' meeting.
    Mendell JR; Csimma C; McDonald CM; Escolar DM; Janis S; Porter JD; Hesterlee SE; Howell RR
    Muscle Nerve; 2007 Jan; 35(1):8-16. PubMed ID: 17068768
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Kennedy version of the Drug Regulation Reform Act.
    Greenberg RB
    Am J Hosp Pharm; 1979 Sep; 36(9):1230-4. PubMed ID: 386790
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New drug and antibiotic regulations--FDA. Proposed rule.
    Fed Regist; 1982 Oct; 47(202):46622-66. PubMed ID: 10262075
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Food and Drug Administration perspective: use of an investigational drug in a medical emergency.
    Schultheis LW; Rappaport BA
    Anesth Analg; 2007 Mar; 104(3):479-80. PubMed ID: 17312189
    [No Abstract]   [Full Text] [Related]  

  • 39. Cost and regulation of drugs.
    Jacox A; Kolassa M
    Nurs Econ; 1992; 10(1):66-9. PubMed ID: 1732821
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Update on medical and regulatory issues pertaining to compounded and FDA-approved drugs, including hormone therapy.
    Pinkerton JV; Pickar JH
    Menopause; 2016 Feb; 23(2):215-23. PubMed ID: 26418479
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.